B Cell Lymphoma
News
CAR T-cell therapy will soon be available in England, NHS says
The National Health Service (NHS) of England has announced that tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy,...
News
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
Predicting early outcomes in DLBCL
Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients...
News
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
NICE says CAR T-cell therapy isn’t cost-effective
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending against the use of axicabtagene ciloleucel (...
News
European Commission approves first CAR T-cell therapies
Tisagenlecleucel and axicabtagene ciloleucel can now be marketed throughout Europe.
News
EC approves CAR T-cell therapy for DLBCL, PMBCL
The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta®) to treat two...
News
ctDNA predicts early outcomes in DLBCL
Adding measurements of circulating tumor DNA to established risk factors could help create a profile of an overall picture of likely outcomes.
News
EC approves CAR T-cell therapy for ALL, DLBCL
The European Commission (EC) has granted approval for tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy targeting CD19...
News
FDA approves new use for ibrutinib in WM
The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica®) for use in combination with rituximab to treat adults with...